24,29 $
0,50 % heute
Nasdaq, 28. Oktober, 21:00 Uhr
ISIN
US26817R1086
Symbol
DYN
Berichte

Dyne Therapeutics Inc Aktie News

Positiv
The Motley Fool
etwa 24 Stunden alt
A peer is being acquired for a very high premium. The market is clearly thinking Dyne might be next on a potential buyer's shopping list.
Positiv
Market Watch
ein Tag alt
Dyne Therapeutics' stock sees record rally, but one analyst says it could still climb a lot further, after a rival got bought out for a big premium.
Positiv
Seeking Alpha
20 Tage alt
Dyne Therapeutics received positive FDA feedback enabling a registrational cohort for z-basivarsen in DM1, with Accelerated Approval possible using vHOT as intermediate efficacy endpoint. DYN expects key catalysts: DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late 2026. The pipeline includes zeleciment rostudirsen for DMD e...
Neutral
GlobeNewsWire
22 Tage alt
- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall disease burden reported by both patients and physicians - WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.
Neutral
GlobeNewsWire
26 Tage alt
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company.
Neutral
GlobeNewsWire
29 Tage alt
- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 -
Neutral
Seeking Alpha
etwa 2 Monate alt
Dyne Therapeutics, Inc. (NASDAQ:DYN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants John Cox - CEO, President & Director Erick Lucera - CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All r...
Neutral
GlobeNewsWire
2 Monate alt
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen